A pilot study of rituximab in patients with recurrent, classic Hodgkin disease (Q47748021)

5 February 2018

title

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease (English)

1 reference

5 February 2018

0 references

1 reference

Anas Younes

1

1 reference

5 February 2018

Jorge Romaguera

2

1 reference

5 February 2018

Frederick Hagemeister

3

1 reference

5 February 2018

Peter McLaughlin

4

1 reference

5 February 2018

Maria Alma Rodriguez

5

1 reference

5 February 2018

Paolo Fiumara

6

1 reference

5 February 2018

Andre Goy

7

1 reference

5 February 2018

Sima Jeha

8

1 reference

5 February 2018

John T Manning

9

1 reference

5 February 2018

Dan Jones

10

1 reference

5 February 2018

Lynne V Abruzzo

11

1 reference

5 February 2018

L Jeffrey Medeiros

12

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 2003

1 reference

5 February 2018

published in

Cancer

1 reference

5 February 2018

volume

98

1 reference

5 February 2018

issue

2

1 reference

5 February 2018

page(s)

310-314

1 reference

5 February 2018

Reed-Sternberg cells and the TNF family of receptors/ligands

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

CD30 ligand is expressed on resting normal and malignant human B lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Serum cytokine levels correlate with clinical parameters in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Hodgkin's disease: a disorder of dysregulated cellular cross-talk

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11511

7 January 2021

Identifiers

DOI

10.1002/CNCR.11511

1 reference

5 February 2018

1 reference

5 February 2018